SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     




J Nucl Med. 2012; 53 (Supplement 1):2066
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Mosci, C.
Right arrow Articles by Iagaru, A.
PubMed
Right arrow Articles by Mosci, C.
Right arrow Articles by Iagaru, A.

General Clinical Specialties

MTA II: Endocrinology/Neuroendocrine Tumor Posters

The role of diagnostic 123I whole body scan prior to ablation of thyroid remnant in patients with papillary thyroid cancer

Camila Mosci1, Haruko Akatsu2, Marina Basina2, Chrysoula Dosiou2 and Andrei Iagaru1

1 Radiology, Nuclear Medicine, Stanford University Medical Center, Stanford, CA 2 Medicine, Endocrinology, Stanford University Medical Center, Stanford, CA

Abstract No. 2066

Objectives: There are controversies regarding the use of 123I whole body scan (WBS) before 131I radioiodine ablation (RAI) of the post-surgical thyroid remnant in patients with papillary thyroid cancer (PTC). The American Thyroid Association’s guidelines state that WBS may be useful before RAI (rating C - expert opinion). Some institutions do not require the WBS as part of the protocol. We therefore analyzed the value of 123I WBS before RAI prior to ablation of thyroid remnant in patients with PTC.

Methods: We reviewed data of 37 consecutive patients with PTC who had total thyroidectomy between August 2007 and January 2008 at our institution. The group included 23 women and 14 men, 13-82 years old (average: 47.4). Three endocrinologists reviewed patients’ data including: sex, age, pathology, Tg, anti-Tg, TSH and ultrasound. After analyzing the data each physician returned a form with the 131I dose that each subject should have received according to the following classification: 50-75 mCi (remnant ablation); 75-125 mCi (lymph nodes metastases); 150 mCi (lung metastases) and 200 mCi (bone metastases). We compared their recommended doses with the actual 131I dose prescribed after analyzing the pre-therapy 123I WBS.

Results: In 20 patients (54.1%) the dose prescribed by the endocrinologists matched the dose administered after analyzing the 123I WBS. In 5 patients (13.5%) the endocrinologists would have given a lower dose and in 10 patients (27%) a higher dose than administered based on the results of the 123I WBS. The 3 endocrinologists recommended doses in disagreement with each other in 2 patients (5.4%) and these were not included in the analysis.

Conclusions: Our study suggests a significant role of the pre-therapy 123I WBS in PTC patients referred for 131I ablation post-thyroidectomy. The actual 131I dose that was administered based on the 123I WBS differed from the dose suggested in the absence of the 123I WBS in 40.5% of the cases





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Mosci, C.
Right arrow Articles by Iagaru, A.
PubMed
Right arrow Articles by Mosci, C.
Right arrow Articles by Iagaru, A.